Concentrations of human cardiac phosphorus metabolites determined by SLOOP 31P NMR spectroscopy
暂无分享,去创建一个
D Hahn | A Haase | A. Haase | S. Neubauer | M. Beer | T. Pabst | D. Hahn | T. Seyfarth | M. von Kienlin | M von Kienlin | M Beer | S Neubauer | T Pabst | W. Landschütz | M. Meininger | M Meininger | W Landschütz | T Seyfarth | M Horn | M. Horn
[1] C. Hardy,et al. Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. , 1990, The New England journal of medicine.
[2] O. Lutz,et al. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. , 1998, Circulation.
[3] C J Hardy,et al. Phosphate metabolite imaging and concentration measurements in human heart by nuclear magnetic resonance , 1990, Magnetic resonance in medicine.
[4] C. Hardy,et al. Proton overhauser enhancements in human cardiac phosphorus NMR spectroscopy at 1.5 T , 1992, Magnetic resonance in medicine.
[5] D. van Ormondt,et al. Analysis of NMR Data Using Time Domain Fitting Procedures , 1992 .
[6] D. van Ormondt,et al. SVD-based quantification of magnetic resonance signals , 1992 .
[7] D. T. Pegg,et al. Theoretical description of depth pulse sequences, on and off resonance, including improvements and extensions thereof , 1985, Magnetic resonance in medicine.
[8] S. Neubauer,et al. 31P Magnetic Resonance Spectroscopy in Dilated Cardiomyopathy and Coronary Artery Disease: Altered Cardiac High‐Energy Phosphate Metabolism in Heart Failure , 1992, Circulation.
[9] A. Staubert,et al. Proton-decoupled myocardial 31P NMR spectroscopy reveals decreased PCr/Pi in patients with severe hypertrophic cardiomyopathy. , 1997, The American journal of cardiology.
[10] C. Hardy,et al. Correcting human heart 31P NMR spectra for partial saturation. Evidence that saturation factors for PCr/ATP are homogeneous in normal and disease states , 1991 .
[11] K. Uğurbil,et al. NMR chemical shift imaging in three dimensions. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[12] Vanhamme,et al. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge , 1997, Journal of magnetic resonance.
[13] T. Inubushi,et al. Quantitative measurements of cardiac phosphorus metabolites in coronary artery disease by 31P magnetic resonance spectroscopy. , 1995, Circulation.
[14] C. V. van Echteld,et al. Saturation correction in human cardiac 31P MR spectroscopy at 1.5 T , 1994, NMR in biomedicine.
[15] A. Wechsler,et al. Derangements in myocardial purine and pyrimidine nucleotide metabolism in patients with coronary artery disease and left ventricular hypertrophy. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[16] Markus von Kienlin,et al. Spectral localization with optimal pointspread function , 1991 .
[17] T. Brown,et al. Quantification of phosphorus metabolites from chemical shift imaging spectra with corrections for point spread effects and B1 inhomogeneity , 1998, Magnetic resonance in medicine.
[18] P A Bottomley,et al. Human cardiac high‐energy phosphate metabolite concentrations by 1D‐resolved NMR spectroscopy , 1996, Magnetic resonance in medicine.
[19] P A Bottomley,et al. Optimum flip‐angles for exciting NMR with uncertain T1 values , 1994, Magnetic resonance in medicine.
[20] A Haase,et al. Localized spectroscopy from anatomically matched compartments: improved sensitivity and localization for cardiac 31P MRS in humans. , 1998, Journal of magnetic resonance.
[21] H. Vliegen,et al. Phosphorus magnetic resonance spectroscopy of the human heart: current status and clinical implications. , 1996, European heart journal.
[22] P A Bottomley,et al. MR spectroscopy of the human heart: the status and the challenges. , 1994, Radiology.